SMIM9: A Potential Drug Target and Biomarker (G100132963)

Target Name: SMIM9

NCBI ID: G100132963

SMIM9

Other Name(s): Small integral membrane protein 9 | CXorf68 | small integral membrane protein 9 | SMIM9_HUMAN

SMIM9: A Potential Drug Target and Biomarker

Small molecule inhibitors of metal ion channels (SMIMs) have been identified as potential drug targets in various diseases, including neurodegenerative disorders, pain, and cardiovascular diseases. SMIMs are a novel family of proteins that play a crucial role in cellular signaling, and their dysfunction has been implicated in a wide range of diseases. In this article, we will discuss the potential drug target and biomarker of SMIM9, and its implications for human health.

Potential Drug Target: SMIM9

SMIM9 is a member of the SMIM family, which includes several similar proteins that play a critical role in intracellular signaling. These proteins are involved in a wide range of cellular processes, including cell signaling, cell division, and neurotransmission. SMIM9 is expressed in various tissues and cells, including neurons, glial cells, and immune cells.

SMIM9 has been shown to play a crucial role in pain perception and neurodegenerative disorders. For example, studies have shown that SMIM9 is involved in the development and progression of neurodegenerative disorders, including Alzheimer's disease and Parkinson's disease. SMIM9 has also been shown to play a role in pain perception, with altered levels of SMIM9 being associated with increased pain sensitivity in animals.

Potential Biomarker

SMIM9 is also a potential biomarker for a variety of diseases. For example, altered levels of SMIM9 have been shown to be associated with increased risk of neurodegenerative disorders, including Alzheimer's disease, Parkinson's disease, and other forms of dementia. Additionally, studies have shown that SMIM9 levels are altered in various psychiatric disorders, including major depressive disorder and anxiety disorders.

SMIM9 is also a potential biomarker for cancer, as altered levels of SMIM9 have been shown to be associated with increased cancer risk. Additionally, SMIM9 has been shown to play a role in the development and progression of various diseases, including cardiovascular disease and diabetes.

Conclusion

SMIM9 is a protein that has the potential to be a drug target and biomarker for a variety of diseases. Its involvement in cellular signaling and its association with various diseases make it an attractive target for drug development. Further research is needed to fully understand the role of SMIM9 in disease and its potential as a drug and biomarker.

Protein Name: Small Integral Membrane Protein 9

The "SMIM9 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SMIM9 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets